04:19 PM, 12th May 2025
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2025 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2025.